BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22321214)

  • 1. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
    Chappie T; Humphrey J; Menniti F; Schmidt C
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors.
    Dore A; Asproni B; Scampuddu A; Pinna GA; Christoffersen CT; Langgård M; Kehler J
    Eur J Med Chem; 2014 Sep; 84():181-93. PubMed ID: 25016376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
    Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
    J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
    Banerjee A; Narayana L; Raje FA; Pisal DV; Kadam PA; Gullapalli S; Kumar H; More SV; Bajpai M; Sangana RR; Jadhav S; Gudi GS; Khairatkar-Joshi N; Merugu RR; Voleti SR; Gharat LA
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6747-54. PubMed ID: 24231362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
    Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
    Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
    J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.
    Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
    Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
    Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
    Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Acylhydrazones as inhibitors of PDE10A.
    Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
    Vlasceanu A; Jessing M; Kilburn JP
    Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
    Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
    Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.
    Yang SW; Smotryski J; McElroy WT; Tan Z; Ho G; Tulshian D; Greenlee WJ; Guzzi M; Zhang X; Mullins D; Xiao L; Hruza A; Chan TM; Rindgen D; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Jan; 22(1):235-9. PubMed ID: 22142545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
    Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
    J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS; Patel MR; Talele TT
    Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
    Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.